赛诺菲安万特 SNY 深 沪
等待开盘 12-31 09:30:00 美东时间
48.74
+0.390
+0.81%
华盛通- 最 高48.945
- 今 开48.77
- 成交量 98.86万股
- 最 低 48.66
- 昨 收 48.35
- 总市值 1183.89亿
- 52周最高 58.5164
- 市盈率 静 20.36
- 换手率 0.04%
- 52周最低 44.6168
- 委 比 82.75%
- 总股本 24.29亿
- 历史最高 58.5164
- 量 比 0.69
- 振 幅 0.59%
- 历史最低 15.4368
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana Life Sciences reported the submission of its seventh annual Development Safety Update Report (DSUR) to the FDA, highlighting the excellent safety profile of intranasal foralumab with no drug-related serious adverse events after 37.4 patient-years of cumulative exposure. The FDA's denial of Sanofi’s tolebrutinib for nrSPMS emphasizes the need for safe therapies in neuroinflammatory disorders. Tiziana's intranasal foralumab demonstrates sig...
12-29 13:00
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals is developing TNX-4800, a long-acting monoclonal antibody targeting OspA of Borrelia burgdorferi, for seasonal prophylaxis against Lyme disease. The company plans to meet with the FDA in 2026 to discuss Phase 2/3 development options, including a controlled human infection model (CHIM) and adaptive field studies. TNX-4800 investigational product under GMP is expected to be available for testing in early 2027. With a single sp...
12-29 12:45
Sanofi’s ITP Burden Study Completes, Adding Real‑World Insight for Investors
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Over...
12-27 00:30
美股机会日报 | 26年延续涨势？美股获华尔街齐声唱多；金银价格齐创新高，矿业股盘前普涨
26年延续涨势？美股获华尔街齐声唱多，AI与降息共振下有望四年连涨；贵金属持续狂飙！金银价格齐创新高，矿业股盘前普涨；存储概念再上扬，闪迪、美光盘前涨约2%>>
12-26 23:56
实体瘤免疫治疗困局，换打法了
（来源：深蓝观） 吴妮 | 撰文 又一 | 编辑 TCE之后，BD的风吹向了MCE（髓系细胞衔接器）。 同为免疫细胞衔接器，TCE主要激活T细胞直接...
12-25 21:11
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
12-25 00:06
赛诺菲以22亿美元收购Dynavax 强化疫苗业务布局
①法国制药巨头赛诺菲以约22亿美元现金收购美国疫苗公司Dynavax Technologies，以降低对哮喘药物Dupixent的依赖，实现业务多元化； ②交易将使赛诺菲获得一款已获批的乙型肝炎疫苗和一款处于早期临床试验阶段的实验性带状疱疹疫苗，预计将于2026年第一季度完成。
12-24 23:59
赛诺菲以22亿美元收购Dynavax 强化疫苗业务布局
财联社12月24日讯（编辑 牛占林）法国制药巨头赛诺菲周三宣布，将以约22亿美元(19亿欧元)现金收购美国疫苗公司Dynavax Technologies。这笔...
12-24 23:59
